Register study of people in France eligible for CAR-T therapy
Part of Blood & lymphatic, Cancer clinical trials.
This study collects health data from people in France who received CAR-T treatment or are eligible to receive it. It helps doctors and researchers understand who can get CAR-T and how treatment is used in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be treated in France with CAR-T under the French health access system (or be eligible for it).
- Your CAR-T treatment need must be approved by a specialist cancer team meeting (tumor board) at a qualified center, if being included prospectively.
- If you are alive, you must have been told your data will be used and you must not have said no; if you passed away, you must not have objected while you were alive.
- Your care must be in a qualified French center that activated this data register.
- You must be registered with the French social security system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tissue samples from adults receiving CAR-T cell therapy (an advanced cancer treatment) to understand why it works well for some patients but not others. The goal is to find biological markers that predict treatment success.
This study looks at how patients with blood cancers are managed in real life when they receive CAR-T cell therapy. It helps doctors learn more about how well these treatments work outside of clinical trials.
This study looks at immune system “fingerprints” in people who are planning to receive CAR-T cells. It may help doctors understand how the immune system responds to CAR-T and improve future care.
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
This study is for people with blood cancers who are treated with CAR-T cell therapy. Researchers will follow participants over time to learn more about how this therapy works in the real world.
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Hear when a new Hematopathology Eligible or CAR-t Cell Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.